• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

经动脉化疗栓塞术治疗不可切除肝细胞癌的应用：对 Cochrane 协作组 2011 年评论的回应。

The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011.

机构信息

University of Colorado, Department of Radiology, Aurora, CO 80045, USA.

出版信息

J Vasc Interv Radiol. 2011 Dec;22(12):1693-6. doi: 10.1016/j.jvir.2011.09.014. Epub 2011 Oct 27.

DOI:10.1016/j.jvir.2011.09.014
PMID:22035882
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4332810/
Abstract

This commentary is written in response to a recent Cochrane Collaboration review published in March 2011 (1). The authors of this commentary would like to express their concerns over the conclusions of the Cochrane review, which state, "There is no firm evidence to support or refute transarterial chemoembolization (TACE) or transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC)."

摘要

这篇评论是针对 Cochrane 协作组织于 2011 年 3 月发表的一篇评论（1）而写的。本文作者对 Cochrane 评论的结论表示关注，该结论指出，“没有确凿的证据支持或反驳经动脉化疗栓塞（TACE）或经动脉栓塞（TAE）治疗不可切除的肝细胞癌（HCC）。”

相似文献

1
The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration review of 2011.经动脉化疗栓塞术治疗不可切除肝细胞癌的应用：对 Cochrane 协作组 2011 年评论的回应。
J Vasc Interv Radiol. 2011 Dec;22(12):1693-6. doi: 10.1016/j.jvir.2011.09.014. Epub 2011 Oct 27.
2
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.经动脉（化疗）栓塞治疗不可切除的肝细胞癌。
Cochrane Database Syst Rev. 2011 Mar 16;2011(3):CD004787. doi: 10.1002/14651858.CD004787.pub2.
3
Efficacy and safety of hepatic arterial infusion chemotherapy followed by transarterial embolization for hepatocellular carcinoma.肝动脉灌注化疗后行经动脉栓塞术治疗肝细胞癌的疗效与安全性
Tumori. 2025 Apr;111(2):158-163. doi: 10.1177/03008916251327830. Epub 2025 Mar 18.
4
Conventional transarterial chemoembolization vs microsphere embolization in hepatocellular carcinoma: a meta-analysis.肝细胞癌中传统经动脉化疗栓塞术与微球栓塞术的比较：一项荟萃分析
World J Gastroenterol. 2014 Dec 7;20(45):17206-17. doi: 10.3748/wjg.v20.i45.17206.
5
The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma.肝细胞癌传统经动脉栓塞化疗（TAE/TACE）后主要并发症的发生率及结局
Medicine (Baltimore). 2016 Dec;95(49):e5606. doi: 10.1097/MD.0000000000005606.
6
Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.经动脉（化疗）栓塞术与不干预或安慰剂治疗肝转移瘤的比较。
Cochrane Database Syst Rev. 2020 Mar 12;3(3):CD009498. doi: 10.1002/14651858.CD009498.pub4.
7
Comparison of two transarterial chemoembolization strategies for hepatocellular carcinoma.两种经动脉化疗栓塞策略治疗肝细胞癌的比较。
Anticancer Res. 2014 Dec;34(12):7247-53.
8
Which transarterial therapy is best for hepatocellular carcinoma?--the evidence to date.哪种经动脉治疗对肝细胞癌最有效？——迄今的证据。
J Hepatol. 2010 Sep;53(3):588. doi: 10.1016/j.jhep.2010.01.031. Epub 2010 Mar 24.
9
Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review.经动脉栓塞联合或不联合化疗治疗晚期肝细胞癌：一项系统评价
Tumour Biol. 2014 Sep;35(9):8451-9. doi: 10.1007/s13277-014-2340-z. Epub 2014 Jul 20.
10
Comparison of the Effectiveness of Transarterial Bland Embolization and Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Propensity Score-Matched Study of 1,008 Patients.经动脉单纯栓塞与经动脉化疗栓塞治疗中期肝细胞癌的疗效比较：一项对1008例患者的倾向评分匹配研究
J Vasc Interv Radiol. 2025 Jan;36(1):41-49. doi: 10.1016/j.jvir.2024.09.005. Epub 2024 Sep 17.

引用本文的文献

1
Enhancement of treatment efficacy of hepatic tumours using Trans-arterial-chemoembolization.经动脉化疗栓塞术提高肝肿瘤治疗效果
Am J Cancer Res. 2023 May 15;13(5):1623-1639. eCollection 2023.
2
Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.与肝动脉化疗栓塞术相比，钇-90放射性栓塞术显著延长了肝细胞癌患者的疾病进展时间。
Gastroenterology. 2016 Dec;151(6):1155-1163.e2. doi: 10.1053/j.gastro.2016.08.029. Epub 2016 Aug 27.
3
Intermediate-stage HCC--upfront resection can be feasible.中期肝癌—— upfront切除可能是可行的。 （注：upfront在医学语境中可能不是常用术语，准确含义需结合更多背景，这里直接保留英文，可能翻译得不够准确，正常翻译可译为“直接的”等，但不太能明确在该语境下准确意思）
Nat Rev Clin Oncol. 2015 May;12(5). doi: 10.1038/nrclinonc.2014.122-c4. Epub 2015 Apr 7.
4
Treatment of intermediate-stage hepatocellular carcinoma.中晚期肝细胞癌的治疗。
Nat Rev Clin Oncol. 2014 Sep;11(9):525-35. doi: 10.1038/nrclinonc.2014.122. Epub 2014 Aug 5.
5
Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations.经动脉栓塞疗法治疗肝细胞癌：CEPO综述与临床建议
HPB (Oxford). 2015 Jan;17(1):52-65. doi: 10.1111/hpb.12273. Epub 2014 Jun 24.
6
Chemoembolization of hepatocellular carcinoma.肝细胞癌的化疗栓塞术
Semin Intervent Radiol. 2013 Mar;30(1):3-11. doi: 10.1055/s-0033-1333648.
7
Chemoembolization in patients with hepatocellular carcinoma.肝细胞癌患者的化疗栓塞术
Liver Cancer. 2012 Jun;1(1):41-50. doi: 10.1159/000339019.
8
Transarterial chemoembolization for pain relief in patients with hypervascular painful metastatic spinal tumors refractory to percutaneous vertebroplasty.经动脉化疗栓塞术治疗经皮椎体成形术治疗无效的伴高血运性疼痛转移性脊柱肿瘤患者的疼痛
J Cancer Res Clin Oncol. 2013 Aug;139(8):1343-8. doi: 10.1007/s00432-013-1445-x. Epub 2013 May 16.
9
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma.一项随机的 II/III 期试验，比较了 3 周为一个周期的基于顺铂的序贯经动脉化疗栓塞与单纯栓塞治疗肝细胞癌的效果。
Br J Cancer. 2013 Apr 2;108(6):1252-9. doi: 10.1038/bjc.2013.85. Epub 2013 Feb 28.

本文引用的文献

1
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.经动脉（化疗）栓塞治疗不可切除的肝细胞癌。
Cochrane Database Syst Rev. 2011 Mar 16;2011(3):CD004787. doi: 10.1002/14651858.CD004787.pub2.
2
The placebo mystique: Implications for clinical trial methodology.安慰剂的神秘性：对临床试验方法的影响。
J Paediatr Child Health. 2011 Jun;47(6):361-6. doi: 10.1111/j.1440-1754.2010.01983.x. Epub 2011 Feb 11.
3
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.中晚期肝细胞癌治疗策略的演进：经动脉化疗栓塞治疗的现有证据和专家意见
Cancer Treat Rev. 2011 May;37(3):212-20. doi: 10.1016/j.ctrv.2010.07.006. Epub 2010 Aug 17.
4
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma.一项针对肝细胞癌随机临床试验中未治疗患者生存率的荟萃分析。
Hepatology. 2010 Apr;51(4):1274-83. doi: 10.1002/hep.23485.
5
Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.钇 90 放射性栓塞与经导管动脉化疗栓塞治疗不可切除肝细胞癌的比较。
J Vasc Interv Radiol. 2010 Feb;21(2):224-30. doi: 10.1016/j.jvir.2009.10.013. Epub 2009 Dec 21.
6
Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients.三药经导管动脉化疗栓塞治疗不可切除肝细胞癌：124 例连续患者的生存评估。
AJR Am J Roentgenol. 2009 Dec;193(6):1665-71. doi: 10.2214/AJR.08.1806.
7
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.多柔比星洗脱微球栓塞治疗肝细胞癌的前瞻性随机研究：PRECISION V 研究结果。
Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52. doi: 10.1007/s00270-009-9711-7. Epub 2009 Nov 12.
8
Declaration of Helsinki, 2008: implications for stakeholders in research.《赫尔辛基宣言》，2008年：对研究利益相关者的影响
J Postgrad Med. 2009 Apr-Jun;55(2):131-4. doi: 10.4103/0022-3859.52846.
9
A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.经导管动脉化疗栓塞术联合碘油、多柔比星和顺铂与静脉多柔比星治疗不可切除肝细胞癌的随机对照试验。
Eur J Cancer Care (Engl). 2009 Sep;18(5):492-9. doi: 10.1111/j.1365-2354.2008.00984.x.
10
Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).多中心随机III期试验：比较单独使用他莫昔芬或联合经动脉碘化油化疗栓塞治疗肝硬化患者不可切除肝细胞癌（法语国家消化肿瘤学联合会9402）
Eur J Cancer. 2008 Mar;44(4):528-38. doi: 10.1016/j.ejca.2008.01.004. Epub 2008 Jan 31.